59 th ASH annual ASH Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Editorial Theme | Novel therapies for the treatment of GvHD
Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...
What is new in chronic GvHD?
This interview with Steven Pavletic, National Cancer Institute, Bethesda, US, was based on the question: What is new in chronic graft-versus-host disease?
Subscribe to get the best content related to GvHD delivered to your inbox every month